What the FDA labels say about taking them together
Lonafarnib and midazolam
Lonafarnib's FDA label of July 2, 2025 names midazolam in its contraindications section; the midazolam labels PlainMeds reads (4) do not name lonafarnib. The lonafarnib label: “CONTRAINDICATIONS ZOKINVY is contraindicated in patients taking: Strong CYP3A inhibitors Strong or moderate CYP3A inducers Midazolam Lovastatin, simvastatin, or atorvastatin Strong CYP3A inhibitors. …”
Check it at the source: the lonafarnib FDA label on DailyMed (effective July 2, 2025, Sentynl Therapeutics, Inc.); the midazolam FDA label on DailyMed (effective January 1, 2024, Fresenius Kabi USA, LLC).
What does the lonafarnib label say about midazolam?
Lonafarnib label, contraindicationsCONTRAINDICATIONS ZOKINVY is contraindicated in patients taking: Strong CYP3A inhibitors [see Drug Interactions ( 7.1 )] Strong or moderate CYP3A inducers [see Drug Interactions ( 7.1 )] Midazolam [see Drug Interactions ( 7.2 )] Lovastatin, simvastatin, or atorvastatin [see Drug Interactions ( 7.2 )] Strong CYP3A inhibitors. ( 4 ) Strong or moderate CYP3A inducers. ( 4 ) Midazolam. ( 2.3 , 4 ) Lovastatin, simvastatin, or atorvastatin.
Lonafarnib label, drug interactionsClinically Significant Drug Interactions (Drugs Affected by ZOKINVY) CYP3A Substrates Clinical Impact Lonafarnib is a strong CYP3A mechanism-based inhibitor. Coadministration of ZOKINVY with a CYP3A substrate increases the AUC and C max of the CYP3A substrate [see Clinical Pharmacology ( 12.3 )] which may increase the risk of the CYP3A substrate's adverse reactions, including myopathy or rhabdomyolysis (with statins), or extreme sedation or respiratory depression (with midazolam). Prevention or Management HMG CoA reductase inhibitors (“Statins”) Coadministration of ZOKINVY with lovastatin, simvastatin, or atorvastatin is contraindicated [see Contraindications ( 4 )]. …
Source: FDA drug label (Zokinvy), Sentynl Therapeutics, Inc., effective July 2, 2025 (SPL set 97391d0c-943e-4c5a-8423-68e163aa7f50), via openFDA; the full label on DailyMed
What does the midazolam label say about lonafarnib?
Midazolam's label (effective January 1, 2024) and its 3 other brand-application labels do not name lonafarnib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Midazolam), Fresenius Kabi USA, LLC, effective January 1, 2024 (SPL set 1cc9ba6e-fa1b-405e-9de8-720c567b2a73), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lonafarnib | Midazolam | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.233 per mL 2 mg/2 mL vial |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once